|Articles|April 5, 2023
Pharma USA 2023: IRA Impact on Patients
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
4
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
5
